New lung fibrosis drug takes first step: safety check in healthy people
NCT ID NCT06267183
First seen Mar 15, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study is an early safety check for a new drug called SV001, which may one day treat idiopathic pulmonary fibrosis (a serious lung disease). It involves 53 healthy adults in China who will receive either a single dose of SV001 or a placebo. The main goal is to see if the drug is safe and how the body processes it, not yet to test if it works for the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Xuhui District Central Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.